Chia Nan University of Pharmacy & Science Institutional Repository:Item 310902800/32177
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 17760/20057 (89%)
造访人次 : 8024427      在线人数 : 589
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧:
  • 您可在西文检索词汇前后加上"双引号",以获取较精准的检索结果
  • 若欲以作者姓名搜寻,建议至进阶搜寻限定作者字段,可获得较完整数据
  • 进阶搜寻


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.cnu.edu.tw/handle/310902800/32177


    標題: Appropriate composites of cefoperazone-sulbactam against multidrug-resistant organisms
    作者: Lai, Chih-Cheng
    Chen, Chi-Chung
    Lu, Ying-Chen
    Lin, Tsuey-Pin
    Chuang, Yin-Ching
    Tang, Hung-Jen
    貢獻者: Chi Mei Med Ctr, Dept Intens Care Med
    Chi Mei Med Ctr, Dept Med Res
    Natl Chiayi Univ, Dept Food Sci
    Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr
    Chi Mei Med Ctr, Dept Internal Med
    Chi Mei Med Ctr, Dept Med
    關鍵字: cefoperazone-sulbactam
    extended-spectrum beta-lactamases
    Escherichia coli
    Klebsiella pneumoniae
    multidrug-resistant organisms
    日期: 2018
    上傳時間: 2019-11-15 15:43:53 (UTC+8)
    出版者: DOVE MEDICAL PRESS LTD
    摘要: Objectives: This study aims to assess the in vitro activity of different cefoperazone-sulbactam ratios against different multidrug-resistant organisms (MDROs). Materials and methods: Minimum inhibitory concentrations (MICs) and susceptibility rates of cefoperazone, sulbactam and cefoperazone-sulbactam at fixed ratios of 2:1, 1:1 and 1:2 against 344 MDRO clinical isolates, including extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli (n=58), ESBL-producing Klebsiella pneumoniae (n=58), carbapenem-resistant Enterobacteriaceae (n=57), carbapenem-resistant Pseudomonas aeruginosa (n=49) and carbapenem-resistant Acinetobacter baumannii (n=122), were measured. Results: Combined treatment with sulbactam and cefoperazone resulted in decreased MIC50 values across all MDROs, as well as decreases in most MIC90 values, except for carbapenem-resistant Enterobacteriaceae and carbapenem-resistant P. aeruginosa (MIC90 values remained >64 mg/L). Susceptibility rates of treatment with cefoperazone alone against all MDROs were much lower than that of cefoperazone-sulbactam combination (all P<0.05), except in carbapenem-resistant P. aeruginosa. Additionally, the susceptibility rate gradually increased as the ratio of cefoperazone-sulbactam was adjusted from 2:1 to 1:1 and to 1:2 for carbapenem-resistant Enterobacteriaceae, ESBL-producing K. pneumoniae and carbapenem-resistant A. baumannii. There were no significant ratio-dependent changes in susceptibility rates with cefoperazone-sulbactam in carbapenem-resistant P. aeruginosa. Conclusion: Adding sulbactam enhances cefoperazone activity against most MDROs excluding carbapenem-resistant P. aeruginosa, and the activity of cefoperazone-sulbactam against these MDROs is greatest at a ratio of 1: 2, followed by ratios of 1:1 and 2:1.
    link: http://dx.doi.org/10.2147/IDR.S175257
    關聯: Infection and Drug Resistance, v.11, pp.1441-1445
    显示于类别:[保健營養系(所) ] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    10.2147-IDR.S175257.pdf132KbAdobe PDF113检视/开启
    index.html0KbHTML171检视/开启


    在CNU IR中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈